SCHEMBL3739637

SCHEMBL3739637

CN1CCN(c2ncc(-c3cc(F)ccc3N3CCN(C(=O)CN4Cc5ccccc5C4=O)CC3)cn2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.44
GRM5 P41594 2/20 0.40
MAPK1 P28482 5/20 0.39
CXCR3 P49682 2/20 0.39
KCNH2 Q12809 2/20 0.39
ALDH1A1 P00352 1/20 0.39
DRD2 P14416 1/20 0.39
DRD5 P21918 1/20 0.39
HTR7 P34969 1/20 0.39
DRD3 P35462 1/20 0.39
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
KDM4E B2RXH2 1/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PREP P48147 2/20 0.38
DPP4 P27487 1/20 0.38
FAP Q12884 1/20 0.38
DPP8 Q6V1X1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL168466 0.95 THRB (0.45) THRBGRM5MAPK1CXCR3KCNH2
SCHEMBL165950 0.92 MAPK1 (0.44) THRBMAPK1
SCHEMBL161709 0.91 CXCR3 (0.48) THRBGRM5MAPK1CXCR3KCNH2
SCHEMBL168582 0.89 THRB (0.43) THRBMAPK1CXCR3KCNH2LMNA
SCHEMBL164930 0.89 CXCR3 (0.39) THRBGRM5MAPK1CXCR3KCNH2
SCHEMBL168581 0.87 THRB (0.42) THRBMAPK1CXCR3KCNH2LMNA
SCHEMBL178151 0.83 ADRA1B (0.44) GRM5
SCHEMBL166876 0.79 CXCR3 (0.59) CXCR3KCNH2HTR7TSHR
SCHEMBL15925510 0.79 CHRM2 (0.36) THRBGRM5CXCR3KCNH2ALDH1A1
SCHEMBL3735656 0.79 MAPT (0.47) THRBMAPK1CXCR3KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US claimed
EP-2424840-B1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-08-06 EP disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
US-8450317-B2 CXCR3 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-28 US disclosed
WO-2010126811-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 WO disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280028-A1 CXCR3 RECEPTOR ANTAGONISTS CXCR3, CXCR1, CXCR2 THRB 1510/4885GRM5 608/4885MAPK1 1967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.